Yasutoshi Kuboki

KRAS ^G12C Inhibition with Sotorasib in Advanced Solid Tumors

David S. Hong, Marwan Fakih, John H. Strickler et al. · New England Journal of Medicine · 2020 · 1.7K citations · Full text

Medicine, Oncology, Oncogenes +1

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

Toshihiko Doi, Kohei Shitara, Yoichi Naito et al. · The Lancet Oncology · 2017 · 501 citations

Medicine, Oncology, Pharmacology +17

Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial

Akihito Kawazoe, Shota Fukuoka, Yoshiaki Nakamura et al. · The Lancet Oncology · 2020 · 270 citations

Medicine, Oncology, Pharmacology +14

Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein–Barr virus status in a large cohort of gastric cancer patients

Akihito Kawazoe, Takeshi Kuwata, Yasutoshi Kuboki et al. · Gastric Cancer · 2016 · 222 citations · Full text

Medicine, Oncology, Pathology +17

TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study

Yasutoshi Kuboki, Tomohiro Nishina, Eiji Shinozaki et al. · The Lancet Oncology · 2017 · 175 citations

Medicine, Oncology, Pharmacology +9